Drugs / IBI302
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05961007 | Nov 2021 → Oct 2023 | diabetic macular edema, wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07275840 | Dec 2025 → Aug 2026 overdue | wet macular degeneration | Innovent Biologics Technology Limited (Shanghai R&D Center) | Recruiting | No outcome recorded |
| Phase 2 | NCT06908876 | Apr 2025 → Dec 2026 expected | diabetic macular edema | Innovent Biologics Technology Limited (Shanghai R&D Center) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05403749 | Jun 2022 → May 2024 | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04820452 | Apr 2021 → Jan 2023 | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05972473 | Sep 2023 → Feb 2027 expected | wet macular degeneration | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04820452 ↗ |
| Known as | Efdamrofusp Alfa | “Intravitreal IBI302(Efdamrofusp Alfa) in Subjects With Neovascular Age-Related Macular Degeneration” NCT05972473 ↗ |
| Route | Intravitreal | “Low dose IBI302 intravitreal injection given as every other month after three loading monthly injection” NCT04820452 ↗ |